Clinical Trial

Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia

Study acronym: XEROCELL
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2023 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-04; most recent amendment 2023-11-16.
Trial Details
NCT Number NCT05857358
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Xerostomia
Enrollment 18 participants
Start Date 2024-01
Primary Completion 2026-02 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2023-11-18